Rheumatoid Arthritis Clinical Benefits from Abatacept, Cytokine Blockers, and Rituximab Are All Linked to Modulation of Memory B Cell Responses
Authors:
- Gregg J. SilvermanGSGregg J. Silverman
- Adam PelzekAPAdam Pelzek
Open Access
- 1 April 2014
- journal article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 41 (5) , 825-828
Abstract
Abatacept (ABA) is a biologic agent with great proven efficacy in patients with rheumatoid arthritis (RA)1. At a molecular level, ABA is composed of recombinant domains of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), fused to the constant region domains of human IgG1, which serves to increase in vivo half-life. This agent binds to CD80/CD86 with a much higher avidity than the CD28 on many T cells, and therefore can act as a physiologic competitive inhibitor that interrupts cell-cell co-stimulatory interactions. In earlier reports, ABA treatment of patients with RA was shown to have striking effects on the modulation of T cell subsets2. The recent report by Scarsi, et al highlights the bidirectional nature of the CD28-CD80/86 interaction and the profound effects that ABA can have on the B cell compartment of the immune system, especially for memory B cells3. With the proven efficacy of the B cell-targeted anti-CD20 agent rituximab (RTX), the central roles of B cells in RA have become well accepted, and B cells also commonly express the co-stimulatory molecules CD80/864. Even at the earliest onset of clinical signs and symptoms, patients with RA display dysregulated immune-cell trafficking and maturation. Compared to healthy subjects, patients with RA also have abnormal levels of circulating memory B cells (identified by CD27 expression), and this may in part reflect their recruitment to the synovial compartment or secondary lymph nodes5. In a small study of 28 patients with RA, Scarsi, et al showed that after 6 months of ABA treatment, patients with clinical responses had significant decreases in levels of switched memory B cells, with persistent decreases in memory B cell subsets also found at 12 months3. ABA therapy also significantly reduced levels of serum total IgG, IgA, and IgM, … Address correspondence to Dr. G. Silverman, Department of Medicine, NYU School of Medicine, 450 E. 29th St., New York, New York 10016, USA. E-mail: Gregg.Silverman{at}nyumc.orgKeywords
This publication has 30 references indexed in Scilit:
- CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patientsBMC Immunology, 2013
- Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trialAnnals of the Rheumatic Diseases, 2013
- The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responsesClinical and Experimental Immunology, 2013
- Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registryAnnals of the Rheumatic Diseases, 2012
- Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trialsAnnals of the Rheumatic Diseases, 2012
- Resolve, revise, and relax: The 3 Rs of B cell repertoire adjustmentImmunology Letters, 2012
- Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)Annals of the Rheumatic Diseases, 2010
- A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosusArthritis Care & Research, 2009
- Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot studyAnnals of the Rheumatic Diseases, 2009
- Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti‐CD20 therapy: the B‐cell roadblock hypothesisImmunological Reviews, 2008